XML 54 R10.htm IDEA: XBRL DOCUMENT v3.20.1
FAIR VALUE
6 Months Ended
Mar. 31, 2020
Fair Value Disclosures [Abstract]  
FAIR VALUE FAIR VALUE

Our “Financial instruments owned” and “Financial instruments sold but not yet purchased” on our Condensed Consolidated Statements of Financial Condition are recorded at fair value under GAAP. For further information about such instruments and our significant accounting policies related to fair value, see Note 2 and Note 4 of our 2019 Form 10-K. The following tables present assets and liabilities measured at fair value on a recurring basis. Netting adjustments represent the impact of counterparty and collateral netting on our derivative balances included on our Condensed Consolidated Statements of Financial Condition. See Note 5 for additional information.
$ in millions
 
Level 1
 
Level 2
 
Level 3
 
Netting
adjustments
 
Balance as of
March 31,
2020
Assets at fair value on a recurring basis:
 
 
 
 
 
 
 
 
 
 
Trading instruments
 
 
 
 
 
 
 
 
 
 
Municipal and provincial obligations
 
$

 
$
14

 
$

 
$

 
$
14

Corporate obligations
 
12

 
9

 

 

 
21

Government and agency obligations
 
30

 
28

 

 

 
58

Agency mortgage-backed securities (“MBS”) and collateralized mortgage obligations (“CMOs”)
 

 
281

 

 

 
281

Non-agency CMOs and asset-backed securities (“ABS”)
 

 
17

 

 

 
17

Total debt securities
 
42


349

 

 

 
391

Equity securities
 
9

 

 

 

 
9

Brokered certificates of deposit
 

 
24

 

 

 
24

Other
 

 

 
21

 

 
21

Total trading instruments
 
51

 
373

 
21

 

 
445

Available-for-sale securities (1)
 
16

 
4,249

 

 

 
4,265

Derivative assets
 
 
 
 
 
 
 
 
 
 
Interest rate - matched book
 

 
351

 

 

 
351

Interest rate - other
 
93

 
266

 

 
(263
)
 
96

Total derivative assets
 
93

 
617

 

 
(263
)
 
447

Other investments - private equity - not measured at net asset value (“NAV”)
 

 

 
30

 

 
30

All other investments
 
192

 
1

 
22

 

 
215

Subtotal
 
352

 
5,240

 
73

 
(263
)
 
5,402

Other investments - private equity - measured at NAV
 
 
 
 
 
 
 
 
 
71

Total assets at fair value on a recurring basis
 
$
352


$
5,240


$
73


$
(263
)

$
5,473

 
 
 
 
 
 
 
 
 
 
 
Liabilities at fair value on a recurring basis:
 
 
 
 
 
 
 
 
 
 
Trading instruments sold but not yet purchased
 
 
 
 
 
 
 
 
 
 
Municipal and provincial obligations
 
$
1

 
$

 
$

 
$

 
$
1

Corporate obligations
 
1

 
7

 

 

 
8

Government and agency obligations
 
6

 

 

 

 
6

Non-agency CMOs and ABS
 

 
6

 

 

 
6

Total debt securities
 
8

 
13

 

 

 
21

Equity securities
 
3

 

 

 

 
3

Other
 

 

 

 

 

Total trading instruments sold but not yet purchased
 
11

 
13

 

 

 
24

Derivative liabilities
 
 
 
 
 
 
 
 
 
 
Interest rate - matched book
 

 
351

 

 

 
351

Interest rate - other
 
102

 
185

 

 
(218
)
 
69

Foreign exchange
 

 
6

 

 

 
6

Equity
 

 
1

 

 

 
1

Total derivative liabilities
 
102

 
543

 

 
(218
)
 
427

Total liabilities at fair value on a recurring basis
 
$
113

 
$
556

 
$

 
$
(218
)
 
$
451



(1)
Substantially all of our available-for-sale securities consist of agency MBS and CMOs. See Note 4 for further information.
$ in millions
 
Level 1
 
Level 2
 
Level 3
 
Netting
adjustments
 
Balance as of
September 30,
2019
Assets at fair value on a recurring basis:
 
 
 
 
 
 
 
 
 
 
Trading instruments
 
 
 
 
 
 
 
 
 
 
Municipal and provincial obligations
 
$

 
$
267

 
$

 
$

 
$
267

Corporate obligations
 
8

 
95

 

 

 
103

Government and agency obligations
 
12

 
67

 

 

 
79

Agency MBS and CMOs
 

 
147

 

 

 
147

Non-agency CMOs and ABS
 

 
51

 

 

 
51

Total debt securities
 
20

 
627

 

 

 
647

Equity securities
 
12

 
1

 

 

 
13

Brokered certificates of deposit
 

 
45

 

 

 
45

Other
 

 

 
3

 

 
3

Total trading instruments
 
32

 
673

 
3

 

 
708

Available-for-sale securities (1)
 
10

 
3,083

 

 

 
3,093

Derivative assets
 
 
 
 
 
 
 
 
 
 
Interest rate - matched book
 

 
280

 

  

 
280

Interest rate - other
 
3

 
182

 

 
(127
)
 
58

Total derivative assets
 
3


462




(127
)

338

Other investments - private equity - not measured at NAV
 

 

 
63

 

 
63

All other investments
 
194

 
1

 
24

 

 
219

Subtotal
 
239

 
4,219

 
90

 
(127
)
 
4,421

Other investments - private equity - measured at NAV
 
 
 
 
 
 
 
 
 
83

Total assets at fair value on a recurring basis
 
$
239

 
$
4,219

 
$
90

 
$
(127
)
 
$
4,504

 
 
 
 
 
 
 
 
 
 
 
Liabilities at fair value on a recurring basis:
 
 
 
 
 
 
 
 
 
 
Trading instruments sold but not yet purchased
 
 
 
 
 
 
 
 
 
 
Corporate obligations
 
$
2

 
$
20

 
$

 
$

 
$
22

Government and agency obligations
 
269

 

 

 

 
269

Total debt securities
 
271

 
20

 

 

 
291

Equity securities
 
4

 

 

 

 
4

Other
 

 

 
1

 

 
1

Total trading instruments sold but not yet purchased
 
275

 
20

 
1

 

 
296

Derivative liabilities
 
 
 
 
 
 
 
 
 
 
Interest rate - matched book
 

 
280

 

 

 
280

Interest rate - other
 
4

 
142

 

 
(121
)
 
25

Foreign exchange
 

 
2

 

 

 
2

Equity
 

 
6

 

 

 
6

Total derivative liabilities
 
4

 
430

 

 
(121
)
 
313

Total liabilities at fair value on a recurring basis
 
$
279

 
$
450

 
$
1

 
$
(121
)
 
$
609



(1)
Substantially all of our available-for-sale securities consist of agency MBS and CMOs. See Note 4 for further information.

Level 3 recurring fair value measurements

The following tables present the changes in fair value for Level 3 assets and liabilities measured at fair value on a recurring basis. The realized and unrealized gains and losses in the tables may include changes in fair value that were attributable to both observable and unobservable inputs. In the following tables, gains/(losses) on trading instruments are reported in “Principal transactions” and gains/(losses) on other investments are reported in “Other” revenues.
Three months ended March 31, 2020
Level 3 instruments at fair value
 
 
Financial assets
 
Financial liabilities
 
 
Trading instruments
 
Other investments
 
Trading instruments
$ in millions
 
Other
 
Private equity investments
 
All other
 
Other
Fair value beginning of period
 
$
19

 
$
62

 
$
24

 
$
(1
)
Total gains/(losses) included in earnings
 
3

 
(32
)
 
(2
)
 

Purchases and contributions
 
22

 

 

 
1

Sales and distributions
 
(23
)
 

 

 

Transfers:
 
 

 
 

 
 

 
 

Into Level 3
 

 

 

 

Out of Level 3
 

 

 

 

Fair value end of period
 
$
21

 
$
30

 
$
22

 
$

Unrealized gains/(losses) for the period included in earnings for instruments held at the end of the reporting period
 
$
5

 
$
(32
)
 
$
(2
)
 
$


Six months ended March 31, 2020
Level 3 instruments at fair value
 
 
Financial assets
 
Financial liabilities
 
 
Trading instruments
 
Other investments
 
Trading instruments
$ in millions
 
Other
 
Private equity investments
 
All other
 
Other
Fair value beginning of period
 
$
3

 
$
63

 
$
24

 
$
(1
)
Total gains/(losses) included in earnings
 
3

 
(32
)
 
(2
)
 

Purchases and contributions
 
53

 

 

 
2

Sales and distributions
 
(38
)
 
(1
)
 

 
(1
)
Transfers:
 
 

 
 

 
 

 
 

Into Level 3
 

 

 

 

Out of Level 3
 

 

 

 

Fair value end of period
 
$
21

 
$
30

 
$
22

 
$

Unrealized gains/(losses) for the period included in earnings for instruments held at the end of the reporting period
 
$
5

 
$
(32
)
 
$
(2
)
 
$

Three months ended March 31, 2019
Level 3 instruments at fair value
 
 
Financial assets
 
Financial liabilities
 
 
Trading instruments
 
Other investments
 
Trading instruments
$ in millions
 
Other
 
Private equity investments
 
All other
 
Other
Fair value beginning of period
 
$
3

 
$
59

 
$
67

 
$
(4
)
Total gains/(losses) included in earnings
 
(1
)
 

 

 

Purchases and contributions
 
22

 

 

 
4

Sales and distributions
 
(22
)
 

 

 
(7
)
Transfers:
 
 
 
 
 
 
 
 
Into Level 3
 

 

 

 

Out of Level 3
 

 

 

 

Fair value end of period
 
$
2

 
$
59

 
$
67

 
$
(7
)
Unrealized gains/(losses) for the period included in earnings for instruments held at the end of the reporting period
 
$
1

 
$

 
$

 
$


Six months ended March 31, 2019
Level 3 instruments at fair value
 
 
Financial assets
 
Financial liabilities
 
 
Trading instruments
 
Other investments
 
Trading instruments
$ in millions
 
Other
 
Private equity investments
 
All other
 
Other
Fair value beginning of period
 
$
1

 
$
56

 
$
67

 
$
(7
)
Total gains/(losses) included in earnings
 

 

 

 
2

Purchases and contributions
 
60

 
3

 

 
9

Sales and distributions
 
(59
)
 

 

 
(11
)
Transfers:
 
 
 
 
 
 
 
 
Into Level 3
 

 

 

 

Out of Level 3
 

 

 

 

Fair value end of period
 
$
2

 
$
59

 
$
67

 
$
(7
)
Unrealized gains/(losses) for the period included in earnings for instruments held at the end of the reporting period
 
$

 
$

 
$

 
$



The net unrealized losses on our Level 3 private equity investments for the three and six months ended March 31, 2020 were primarily driven by the negative impact of the coronavirus (“COVID-19”) pandemic on certain of our investments.

As of March 31, 2020, 11% of our assets and 1% of our liabilities were measured at fair value on a recurring basis.  In comparison, as of September 30, 2019, 12% of our assets and 2% of our liabilities were measured at fair value on a recurring basis. As of March 31, 2020 and September 30, 2019, instruments measured at fair value on a recurring basis categorized as Level 3 represented 1% and 2%, respectively, of our assets measured at fair value.

Quantitative information about level 3 fair value measurements

The following tables present the valuation techniques and significant unobservable inputs used in the valuation of certain of our private equity investments classified as level 3. These inputs represent those that a market participant would take into account when pricing these instruments. Weighted averages are calculated by weighting each input by the relative fair value of the related financial instrument. Certain investments are valued initially at transaction price and updated as other investment-specific events take place which indicate that a change in the carrying values of these investments is appropriate. Other investment-specific events include such events as our periodic review, significant transactions occur or new developments become known.

Recurring measurements
 
Fair value at March 31, 2020
 
Valuation technique(s)
 
Unobservable input
 
Range
(weighted-average)
$ in millions
 
 
 
 
 
 
 
 
Other investments - private equity investments (not measured at NAV)
 
$
30

 
Discounted cash flow, transaction price or other investment-specific events
 
Discount rate
 
25
%
 
 
 
 
 
 
Terminal earnings before interest, tax, depreciation and amortization (“EBITDA”) multiple
 
9.0x

 
 
 
 
 
 
Terminal year
 
2021 - 2042 (2024)

 
 
Fair value at September 30, 2019
 
 
 
 
 
 
Other investments - private equity investments (not measured at NAV)
 
$
63

 
Discounted cash flow, transaction price or other investment-specific events
 
Discount rate
 
25
%
 
 
 
 
 
 
Terminal EBITDA multiple
 
12.5x

 
 
 
 
 
 
Terminal year
 
2021 - 2042 (2022)



Qualitative information about unobservable inputs

For our recurring fair value measurements categorized within Level 3 of the fair value hierarchy, the sensitivity of the fair value measurement to changes in significant unobservable inputs and interrelationships between those unobservable inputs are described in the following section.

Private equity investments

The significant unobservable inputs used in the fair value measurement of private equity investments generally relate to the financial performance of the investment entity and the market’s required return on investments from entities in industries in which we hold investments. Increases in the discount rate would have resulted in a lower fair value measurement. Increases in the terminal EBITDA multiple would have resulted in a higher fair value measurement. Increases in the terminal year are dependent upon each investment’s strategy, but generally result in a lower fair value measurement.

Investments in private equity measured at net asset value per share

As more fully described in Note 2 of our 2019 Form 10-K, as a practical expedient, we utilize NAV or its equivalent to determine the recorded value of a portion of our private equity investments portfolio. We utilize NAV when the fund investment does not have a readily determinable fair value and the NAV of the fund is calculated in a manner consistent with the measurement principles of investment company accounting, including measurement of the investments at fair value.

Our private equity portfolio includes various direct investments, as well as investments in third-party private equity funds and various legacy private equity funds which we sponsor. The portfolio is primarily invested in a broad range of industries including leveraged buyouts, growth capital, distressed capital, venture capital and mezzanine capital. Due to the closed-end nature of certain of our fund investments, such investments cannot be redeemed directly with the funds. Our investment is monetized by distributions received through the liquidation of the underlying assets of those funds, the timing of which is uncertain.

The following table presents the recorded value and unfunded commitments related to our private equity investments portfolio.
$ in millions
 
Recorded value
 
Unfunded commitment
March 31, 2020
 
 
 
 
Private equity investments measured at NAV
 
$
71

 
$
12

Private equity investments not measured at NAV
 
30

 
 
Total private equity investments 
 
$
101

 
 
 
 
 
 
 
September 30, 2019
 
 
 
 
Private equity investments measured at NAV
 
$
83

 
$
15

Private equity investments not measured at NAV
 
63

 
 
Total private equity investments
 
$
146

 
 


Of the total private equity investments, the portions we owned were $79 million and $99 million as of March 31, 2020 and September 30, 2019, respectively. The portions of the private equity investments we did not own were $22 million and $47 million as of March 31, 2020 and September 30, 2019, respectively, and were included as a component of noncontrolling interests on our Condensed Consolidated Statements of Financial Condition.

Many of these fund investments meet the definition of prohibited covered funds as defined by the Volcker Rule enacted pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. We have received approval from the Board of Governors of the Federal Reserve System (the “Fed”) to continue to hold the majority of our covered fund investments until July 2022. However, our current focus is on the divestiture of this portfolio.

Financial instruments measured at fair value on a nonrecurring basis

The following table presents assets measured at fair value on a nonrecurring basis along with the valuation techniques and significant unobservable inputs used in the valuation of the assets classified as level 3. These inputs represent those that a market participant would take into account when pricing these instruments. Weighted averages are calculated by weighting each input by the relative fair value of the related financial instrument.
$ in millions
 
Level 2
 
Level 3
 
Total fair value
 
Valuation technique(s)
 
Unobservable input
 
Range
(weighted-average)
March 31, 2020
 
 
 
 
 
 
 
 
 
 
 
 
Bank loans, net:
 
 
 
 
 
 
 
 
 
 
 
 
Impaired loans: residential
 
$
4

 
$
14

 
$
18

 
Discounted cash flow
 
Prepayment rate
 
7 yrs. - 12 yrs. (10.4 yrs.)
Impaired loans: corporate
 
$

 
$
10

 
$
10

 
Collateral or discounted cash flow (1)
 
Not meaningful (1)
 
Not meaningful (1)
Loan held for sale
 
$
67

 
$

 
$
67

 
N/A
 
N/A
 
N/A
Other assets: other real estate owned
 
$
2

 
$

 
$
2

 
N/A
 
N/A
 
N/A
 
 
 
 
 
 

 
 
 
 
 
 
September 30, 2019
 
 
 
 
 
 
 
 
 
 
 
 
Bank loans, net:
 
 
 
 
 
 
 
 
 
 
 
 
Impaired loans: residential
 
$
7

 
$
14

 
$
21

 
Discounted cash flow
 
Prepayment rate
 
7 yrs. - 12 yrs. (10.4 yrs.)
Impaired loans: corporate
 
$

 
$
21

 
$
21

 
Collateral or discounted cash flow (1)
 
Not meaningful (1)
 
Not meaningful (1)
Loan held for sale
 
$
66

 
$

 
$
66

 
N/A
 
N/A
 
N/A
Other assets: other real estate owned
 
$
1

 
$

 
$
1

 
N/A
 
N/A
 
N/A

(1)
The valuation techniques used for the corporate loans are based on collateral value less selling costs for the collateral dependent loans and discounted cash flows for impaired loans that are not collateral dependent.

Financial instruments not recorded at fair value

Many, but not all, of the financial instruments we hold were recorded at fair value on the Condensed Consolidated Statements of Financial Condition. The following table presents the estimated fair value and fair value hierarchy of financial assets and liabilities that are not recorded at fair value in accordance with GAAP on the Condensed Consolidated Statements of Financial Condition at March 31, 2020 and September 30, 2019. This table excludes financial instruments that are carried at amounts which approximate fair value. Refer to Note 4 of our 2019 Form 10-K for a discussion of the fair value hierarchy classification of our financial instruments that are not recorded at fair value.
$ in millions
 
Level 2
 
Level 3
 
Total estimated fair value
 
Carrying amount
March 31, 2020
 
 
 
 
 
 
 
 
Financial assets:
 
 
 
 
 
 
 
 
Bank loans, net
 
$
56

 
$
21,823

 
$
21,879

 
$
21,693

Financial liabilities:
 
 
 
 
 
 

 
 
Bank deposits - certificates of deposit
 
$

 
$
1,191

 
$
1,191

 
$
1,150

Senior notes payable
 
$
2,208

 
$

 
$
2,208

 
$
2,044

 
 
 
 
 
 
 
 
 
September 30, 2019
 
 
 
 
 
 
 
 
Financial assets:
 
 
 
 
 
 
 
 
Bank loans, net
 
$
75

 
$
20,710

 
$
20,785

 
$
20,783

Financial liabilities:
 
 
 
 
 
 

 
 
Bank deposits - certificates of deposit
 
$

 
$
617

 
$
617

 
$
605

Senior notes payable
 
$
1,760

 
$

 
$
1,760

 
$
1,550